-
21-01-2017, 12:27 AM
#5151
Junior Member
All is very quiet regarding announcements from the company. I presume the present predicted profit is still on track with just over 2 months left of the financial year. Then there will be the next financial year where they need to indicate projected turnover and profitability. The next 3 months will be very interesting! The share price will react accordingly!
-
21-01-2017, 03:15 PM
#5152
I think we have to consider the possibility that the lack of news is real and represents a lack of momentum presently. After all, the company did say it was pausing to regroup. I can't see any way of forming any clear opinion on the outlook from current news and have changed my own position from "optimistic" to "simply don't know". The company said it was "upbeat" last year https://www.nzx.com/companies/BLT/announcements/282826 and "convinced growth will be the feature of this business for many years to come" https://www.nzx.com/files/attachments/237641.pdf, but that doesn't mean things are rocketing along presently.
I remain cautious. Hopeful, but cautious.
-
21-01-2017, 06:35 PM
#5153
Member
Originally Posted by simla
I think we have to consider the possibility that the lack of news is real and represents a lack of momentum presently. After all, the company did say it was pausing to regroup. I can't see any way of forming any clear opinion on the outlook from current news and have changed my own position from "optimistic" to "simply don't know". The company said it was "upbeat" last year https://www.nzx.com/companies/BLT/announcements/282826 and "convinced growth will be the feature of this business for many years to come" https://www.nzx.com/files/attachments/237641.pdf, but that doesn't mean things are rocketing along presently.
I remain cautious. Hopeful, but cautious.
Can we take some comfort from the Reporting Obligations?
No news so alls well.
Pat
Prediction is hard even with the crystal ball.
-
23-01-2017, 09:45 AM
#5154
Member
BLT
23/01/2017 09:27
GENERAL
NOT PRICE SENSITIVE
REL: 0927 HRS BLIS Technologies Limited
GENERAL: BLT: New European study
MEDIA RELEASE
January 23, 2017.
New European study shows benefits of Kiwi-developed probiotic in young
children
A recent study by Italy's pre-eminent researcher into probiotics has
concluded that a Kiwi-developed oral probiotic, BLIS K12 TM, is associated
with a significant reduction in ear and throat infections (acute otitis media
and streptococcal pharyngitis) among children attending their first year of
kindergarten.
BLIS K12 is the world's first probiotic for the mouth and throat.
This news comes as New Zealand children are about to head back to school and
pre-school where they will be exposed to a range of pathogens that can cause
ear and throat infections.
The study, published in the European Review for Medical and Pharmacological
Science by a team from Velleja Research led by Dr Francesco Di Pierro, ran a
randomized trial among 222 enrolled children attending the first year of
kindergarten. The treated group of 111 children received a daily oral dose
of BLIS K12 for six months. A control group (that received no BLIS K12) was
also monitored.
During the six-month trial the incidence of throat and ear infections
(streptococcal pharyngo-tonsillitis and acute otitis media) was approximately
16 percent and 44 percent respectively in the treated group. This compared to
the higher incidence of 48 percent and 80 percent respectively in the control
group.
During a three-month follow-up period in a subgroup of children, the
corresponding rates of infection were 15 percent and 12 percent in the
treated group and 26 percent and 36 percent in the controls, suggesting a
potential prolonged benefit.
The authors reported that the results appear to demonstrate for the first
time that the preventive administration of BLIS K12 could generate positive
health outcomes even in very young children who have not been pre-selected as
prone to recurrent streptococcal infection or acute otitis media.
BLIS K12 or Streptococcus salivarius K12 is an advanced probiotic strain
hostile to the growth of Streptococcus pyogenes, the most important bacterial
cause of throat infections in humans.
"BLIS K12 populates the mouth and throat with a beneficial strain of
Streptococcus salivarius which crowds out the bad bacteria. Think of it like
a forcefield in your throat that stops the bad bacteria invading. It is
effective in the prevention of Streptococcal throat infections which, if left
untreated, can lead to more serious health conditions," explains BLIS
Technologies chief technology officer, Dr John Hale.
BLIS K12 is present in ThroatGuard Lozenges and ToddlerProtect powder which
are available over-the-counter from pharmacies and online at www.blis.co.nz
ends
About BLIS Technologies
Blis Technologies Limited was formed to commercialise advanced probiotic
strains that work outside the gut. Professor John Tagg of the Microbiology
department at the University of Otago gathered and extensively catalogued a
collection of more than 2000 of these bacteria over a period of more than 30
years. Blis Technologies acquired the rights to this unique collection of
bacteria from the University of Otago in New Zealand and in July 2001, the
company was listed on the New Zealand Stock Exchange. In the time since its
listing on the New Zealand Stock Exchange, the company has developed consumer
products for throat health, halitosis (bad breath), immune support and teeth
and gum health.
Media contact:
Brenda Saunders, Trio Communications, Auckland. Phone: 021 777 171.
End CA:00295836 For:BLT Type:GENERAL Time:2017-01-23 09:27:19
-
23-01-2017, 09:54 AM
#5155
Good that Blis noted that you guys were getting a bit depressed ......so made an announcement to cheer you up and give you further hope.
Good on em.
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
-
23-01-2017, 05:10 PM
#5156
Member
Originally Posted by winner69
Good that Blis noted that you guys were getting a bit depressed ......so made an announcement to cheer you up and give you further hope.
Good on em.
Up 13.6% today ...... that cheers me up!!
-
23-01-2017, 06:04 PM
#5157
I think the preventive effect is very important, and hopefully there will be more good research.
Then it will be up to DHBs or equivalent funders in other countries to do the maths. The article below quotes the clinical director of Mana Kidz saying that each case of rheumatic fever / rheumatic heart disease has a lifetime cost of a million dollars. That group though does have a vested interest in getting lots of government funding - it seems a very specialist-labour intensive programme plus antibiotics. Blis would have to be cheaper, surely, and pro rather than anti biotic.
http://www.newshub.co.nz/home/new-ze...e-throats.html
-
24-01-2017, 12:03 PM
#5158
Originally Posted by gmatt
Up 13.6% today ...... that cheers me up!!
I suspect yesterday's little rally might run out of steam today. It seemed a bit of an over-reaction to a non-price sensitive announcement. Then again it probably motivated a bit more interest in BLT ahead of the FY17 year end at 31 March.
They have certainly been quiet since the half-year result announcement in October and the report in November so I hope the silence means they're all heads down and tails up working like crazy to keep the ship steaming ahead. The company must be on track to achieve at least the previously forecast FY17 result otherwise I expect we should have heard by now.
Interesting questions for me are:
a) will BLT exceed the FY17 forecast of $0.7m NPBT - maybe an update to come in February as they did last year?
b) have they made any progress with the trials in China?
c) what has happened in the US following GRAS approval?
d) Is the overall sales growth momentum continuing, particularly in Australasia, Europe and North America?
It will be great if the company can come up with a $1million bottom line for the year - but maybe that might be aiming just a little too high? The SP has been as high as 6.1c in the past year - a repeat seems entirely achievable if forecast results are met or bettered and there's a positive story about future growth.
Hey Brian - how about some news on what's happening down there in Dunedin?
-
01-02-2017, 06:31 AM
#5159
Blisfool
Do you think the new Japanese toothpaste is named after our newish CEO?
As as usual with Blis potentially this is huge
-
04-02-2017, 10:36 AM
#5160
Originally Posted by simla
Yes.
There is also a cat version:
http://item.rakuten.co.jp/cocotte-ve...#blismix_cat_1
It lists "Streptococcus salivarius K12 (Good intraoral bacteria)" in it's raw ingredients list. Both products come in many different sized bags.
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks